Orris

I want to send my thesis as paper presentation in cution this my thesis protocol… make an abstract keeping total number of patient as 20 with 10 in each group

Reading File
Browsing Directory

~/attachments/b034b98e-6ff8-4b12-b757-699a87926cb5

Running Command

cd /tmp/workspace && python3 -c " import pdfplumber with pdfplumber.open('attachments/b034b98e-6ff8-4b12-b757-699a87926cb5/dr itee thesis pdf.pdf') as pdf: print('pages', len(pdf.pages)) text='' for p in pdf.pages: t = p.extract_text() if t: text += t + '\n' open('thesis_text.txt','w').write(text) print(len(text)) "

Reading File
Reading File
Searching Content

"AIM" in ~/thesis_text.txt

Searching Content

"Inclusion criteria" in ~/thesis_text.txt

Searching Content

"randomiz" in ~/thesis_text.txt

Searching Content

"VASI" in ~/thesis_text.txt

Reading File
Based on your thesis protocol (Comparative Efficacy of Topical Tacrolimus 0.1% vs Topical Tofacitinib 2% in Non-Segmental Vitiligo, GMCH-32 Chandigarh), here is a conference-ready abstract with the sample size fixed at 20 patients (10 per group):
Title: Comparative Efficacy and Safety of Topical Tacrolimus 0.1% versus Topical Tofacitinib 2% in the Treatment of Non-Segmental Vitiligo: A Randomized Controlled Trial
Background: Vitiligo is an acquired depigmenting disorder affecting 0.5-1% of the global population, resulting from autoimmune-mediated melanocyte destruction. Existing therapies such as topical corticosteroids, calcineurin inhibitors, and narrowband UVB often yield inconsistent repigmentation. Topical tacrolimus, a calcineurin inhibitor, is an established steroid-sparing option, while topical tofacitinib, a JAK inhibitor targeting the IFN-γ/CXCL9-CXCL10 axis, has shown promising results in preliminary studies. Head-to-head comparative data between these two agents remain limited.
Aim/Objectives: Primary objective was to compare the efficacy of topical tacrolimus 0.1% and topical tofacitinib 2% in achieving repigmentation in non-segmental vitiligo over 16 weeks. Secondary objectives were to compare the time to onset of visible repigmentation and clinician-assessed percentage repigmentation, and to evaluate the safety/adverse effect profile of both agents.
Methods: This prospective, randomized, open-label, parallel-arm controlled study was conducted in the Department of Dermatology, Venereology and Leprosy, GMCH-32, Chandigarh. Twenty patients (age >5 years) with clinically confirmed, stable non-segmental vitiligo (body surface area involvement ≤10%) were randomized by the random table method into two equal groups of 10 patients each. Group A received topical tacrolimus 0.1% ointment twice daily; Group B received topical tofacitinib 2% ointment twice daily, for 16 weeks. Patients were assessed at baseline and at weeks 4, 8, 12 and 16 using the Vitiligo Noticeability Scale (VNS), percentage repigmentation, standardized photographic documentation, and adverse-effect monitoring.
Results: Data collection and follow-up are ongoing / awaited at the time of submission. [Insert: mean repigmentation/VASI change, VNS scores, time to onset, and adverse events for Group A vs Group B once available.]
Conclusion: This randomized comparative trial in 20 patients of non-segmental vitiligo is expected to provide clinically relevant evidence on the relative efficacy and safety of topical tacrolimus 0.1% versus topical tofacitinib 2%, helping guide the choice of steroid-sparing topical agents in vitiligo management.
Keywords: Vitiligo, Tacrolimus, Tofacitinib, JAK inhibitor, Repigmentation
Notes:
  • Word count is ~300, which fits most conference limits (usually 250-300). Tell me the target word/character limit if your conference specifies one and I'll trim it.
  • The Results section is left as a placeholder since your thesis is still at protocol stage - fill in actual values (mean % repigmentation, VNS scores, adverse events) once you have interim or final data, or I can phrase it as "study in progress" if you're presenting before data lock.
  • I can also format this into a Word (.docx) or PDF file matching a specific conference template if you share the submission guidelines/format.
This is a shared conversation. Sign in to Orris to start your own chat.